Amphastar Pharmaceuticals Inc (AMPH)
48.02
+0.14
(+0.29%)
USD |
NASDAQ |
Sep 27, 16:00
47.98
-0.04
(-0.08%)
After-Hours: 20:00
Amphastar Pharmaceuticals Research and Development Expense (Annual): 73.74M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 73.74M |
| December 31, 2022 | 74.77M |
| December 31, 2021 | 60.93M |
| December 31, 2020 | 67.23M |
| December 31, 2019 | 68.85M |
| December 31, 2018 | 57.56M |
| December 31, 2017 | 43.50M |
| Date | Value |
|---|---|
| December 31, 2016 | 41.52M |
| December 31, 2015 | 37.27M |
| December 31, 2014 | 28.87M |
| December 31, 2013 | 33.02M |
| December 31, 2012 | 31.16M |
| December 31, 2011 | 31.05M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
60.93M
Minimum
2021
74.77M
Maximum
2022
69.11M
Average
68.85M
Median
2019
Research and Development Expense (Annual) Benchmarks
| Omeros Corp | 114.87M |
| Harrow Inc | 6.652M |
| PetIQ Inc | -- |
| Amneal Pharmaceuticals Inc | 167.78M |
| Alector Inc | 192.12M |